PD-1 Deficiency Promotes Macrophage Activation and T-Helper Cell Type 1/T-Helper Cell Type 17 Response in...

Area of Science:

• Immunology
• Infectious Diseases
• Mycology

Background:

• Pneumocystis pneumonia (PCP) is an opportunistic infection in immunocompromised individuals.
• The pathogenesis of PCP remains incompletely understood despite its long history.
• The programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway regulates immune responses.

Purpose of the Study:

• To investigate the role of the PD-1/PD-L1 pathway in Pneumocystis infection.
• To evaluate the impact of PD-1 deficiency on immune responses during PCP.
• To explore the therapeutic potential of targeting the PD-1/PD-L1 pathway for PCP.

Main Methods:

• Quantification of PD-1/PD-L1 expression in human PCP patients and murine models using real-time PCR and flow cytometry.
• Assessment of immune responses in wild-type and PD-1 knockout mice infected with Pneumocystis.
• Evaluation of anti-PD-1 antibody treatment in a murine model of PCP.

Main Results:

• Pneumocystis infection significantly upregulates PD-1 and PD-L1 expression.
• PD-1 deficiency enhances macrophage phagocytosis and promotes pulmonary T-helper cell type 1 (Th1)/Th17 responses, aiding Pneumocystis clearance.
• PD-1 deficiency influences macrophage polarization, and anti-PD-1 therapy improves Pneumocystis clearance in mice.

Conclusions:

• The PD-1/PD-L1 pathway plays a critical role in modulating innate and adaptive immunity during Pneumocystis infection.
• Targeting the PD-1/PD-L1 pathway represents a promising immunotherapeutic strategy for managing PCP.